Dust mite immunotherapy has transformed the way doctors manage children with persistent allergies. Dust mites are one of the most common indoor allergens and are a major cause of allergic rhinitis and asthma in children. While inhalers, nasal sprays and antihistamines can control symptoms, they do not address the root cause. This is where standardised dust mite immunotherapy—through tablets such as SENSIMUNE or ACARIZAX—offers long-term relief and disease-modifying benefits.
What is Dust Mite Immunotherapy?
Dust mite immunotherapy works by gradually desensitising the immune system to dust mite allergens. Instead of simply masking symptoms, it retrains the body to tolerate allergens, thereby reducing the intensity of future allergic responses. Immunotherapy can be given as:
- Sublingual Immunotherapy: Available in the form of drops or tablets, which are taken under the tongue daily.
- Subcutaneous injections (SCIT): Small injections are given at 2–4 weeks interval.
Indications for Dust Mite Immunotherapy
Doctors may recommend dust mite immunotherapy for children with confirmed dust mite allergy where:
- The long-standing symptoms affect sleep, school performance, and daily quality of life.
- There is poor response or dependency on long-term medications.
Conditions include:
- Allergic rhinitis
- Allergic conjunctivitis
- Asthma
Benefits of SENSIMUNE and ACARIZAX
Both SENSIMUNE and ACARIZAX are standardised dust mite immunotherapy tablets with proven efficacy and safety in children above a certain age. Key benefits include:
- Long-term relief: Reduces nasal congestion, sneezing, and eye symptoms of allergic rhinitis.
- Improved asthma control: Fewer wheezing episodes, better lung function, and reduced need for inhalers.
- Disease modification: Targets the underlying immune response, not just the symptoms.
- Reduced medication use: Children often need fewer antihistamines or steroids over time.
- Sustained benefit: Even after stopping therapy (usually after 3 years), many children continue to enjoy lasting relief.
Why Standardised Dust Mite Immunotherapy is Better?
SENSIMUNE or ACARIZAX are Standardised Dust Mite Immunotherapy tablets. They undergo rigorous international quality checks to ensure precise allergen dosing and proven clinical efficacy. Standardisation guarantees that every tablet contains the same concentration, which translates into better safety, predictable outcomes, and reliable long-term benefits for children with allergic rhinitis and asthma.
Safety and Duration of Treatment
- These tablets are well-tolerated. Mild throat irritation or itching under the tongue may occur initially but usually improves within days.
- Severe reactions are very rare, but treatment should be started under medical supervision.
- Standard duration is 3 years of daily therapy for best long-term outcomes.
Conclusion
Dust mite immunotherapy with SENSIMUNE or ACARIZAX offers a safe, effective, and long-term solution for children struggling with asthma and allergic rhinitis caused by dust mites. Unlike routine medicines, it modifies the disease course, improving quality of life and reducing the future risk of worsening allergy or asthma. Parents can feel reassured that this treatment addresses the root cause, not just the symptoms.
In case your child is suffering from allergies like allergic rhinitis, allergic conjunctivitis or asthma you need to get in touch with a child allergist or pulmonologist for proper diagnosis and treatment.
